Erix-IT Capsule SR is a combination pharmaceutical formulation containing Esomeprazole 40 mg and Itopride 150 mg, designed for the effective management of gastrointestinal disorders. Esomeprazole, a proton pump inhibitor, acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion and promoting ulcer healing. Itopride, a prokinetic agent, enhances gastrointestinal motility by antagonizing dopamine D2 receptors and inhibiting acetylcholinesterase activity, facilitating gastric emptying and improving symptoms such as bloating, nausea, and early satiety. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, optimizing symptom control and patient compliance. Erix-IT Capsule SR is indicated for the treatment of gastroesophageal reflux disease (GERD), functional dyspepsia, and other acid-related gastrointestinal conditions accompanied by delayed gastric emptying. It is contraindicated in patients with known hypersensitivity to esomeprazole, itopride, or any excipients. Caution is advised in patients with hepatic impairment or a history of cardiac arrhythmias. Common adverse effects may include headache, diarrhea, abdominal discomfort, and dizziness. Erix-IT Capsule SR should be administered as prescribed by a healthcare professional, with monitoring for therapeutic efficacy and potential side effects to ensure optimal patient outcomes.